Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Viridian Therapeutics, Inc. (VRDN : NSDQ)

• Company Description    Viridian Therapeutics Inc. is a biotechnology company advancing new treatments for patients suffering from serious diseases. The company's program includes VRDN-001, which is in clinical stage. Viridian Therapeutics Inc., formerly known as miRagen Therapeutics Inc., is based in BOULDER, Colo. Number of Employees: 143

• Price / Volume Information    Yesterday's Closing Price: $32.31 Daily Weekly Monthly 20 Day Moving Average: 1,577,187 shares Shares Outstanding: 95.44 (millions) Market Capitalization: $3,083.73 (millions) Beta: 0.87 52 Week High: $33.34 52 Week Low: $9.90 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.41% 11.91% 12 Week 64.68% 59.96% Year To Date 68.54% 44.80%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 221 CRESCENT STREET SUITE 103A - WALTHAM,MA 02453 USA ph: 617-272-4600 fax: 760-537-4101 ir@viridiantherapeutics.com http://www.viridiantherapeutics.com

• General Corporate Information    Officers Stephen Mahoney - President; Chief Executive Officer and Director Tomas Kiselak - Chairman Seth Harmon - Chief Financial Officer Sarah Gheuens - Director Peter Harwin - Director Peer Information Viridian Therapeutics, Inc. (CORR.) Viridian Therapeutics, Inc. (RSPI) Viridian Therapeutics, Inc. (CGXP) Viridian Therapeutics, Inc. (BGEN) Viridian Therapeutics, Inc. (GTBP) Viridian Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92790C104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/26/26 Share - Related Items Shares Outstanding: 95.44 Most Recent Split Date: 11.00 (0.07:1) Beta: 0.87 Market Capitalization: $3,083.73 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.89 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.28 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 9.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/26/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.40 Price/Cash Flow: - Price / Sales: 43.56 EPS Growth vs. Year Ago Period: 70.43% vs. Previous Quarter: 66.00% Sales Growth vs. Year Ago Period: 81,958.13% vs. Previous Quarter: 93,993.33% ROE 09/30/25 - -78.50 06/30/25 - -78.95 03/31/25 - -70.61 ROA 09/30/25 - -47.13 06/30/25 - -49.91 03/31/25 - -44.67 Current Ratio 09/30/25 - 11.28 06/30/25 - 11.01 03/31/25 - 19.49 Quick Ratio 09/30/25 - 11.28 06/30/25 - 11.01 03/31/25 - 19.49 Operating Margin 09/30/25 - -426.58 06/30/25 - -112,806.88 03/31/25 - -102,092.39 Net Margin 09/30/25 - -426.58 06/30/25 - -112,806.88 03/31/25 - -102,092.39 Pre-Tax Margin 09/30/25 - -426.58 06/30/25 - -112,806.88 03/31/25 - -102,092.39 Book Value 09/30/25 - 3.85 06/30/25 - 4.00 03/31/25 - 5.09 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.07 06/30/25 - 0.04 03/31/25 - 0.05 Debt-to-Capital 09/30/25 - 3.99 06/30/25 - 2.34 03/31/25 - 3.31

Powered by Zacks Investment Research ©